The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...
We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...
Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
A new study examines how cost, side effects and other factors influence whether people stop GLP-1s, while Noom cuts staff to ...
Teva Pharma Industries Ltd ADR, Allergan PLC, Johnson & Johnson, CVS Health Corp. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...
Novo Nordisk's CagriSema trial raised concerns as patients reported weight loss but significant side effects. Investors ...
Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...
Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...
KELOWNA, BC / ACCESS Newswire / January 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provi ...
Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.
The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback